Antiplatelet Therapy in the Catheterization Laboratory

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

October 15, 2009

Expiration Date:

October 15, 2011

Intended Audience:

The educational activity is designed for all interventional cardiologists, cardiologists, and other health professionals who manage patients with acute coronary syndromes in the setting of the catheterization laboratory.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported by an independent medical educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI – Program Co-Chairman
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular
Program, Brigham and Women’s Hospital and the
VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Boston, MA
Grant/ Research: Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, The
Medicines Company.

Shamir Mehta, MD, MSc, FACC, FRCPC – Program Co-Chairman
Director, Interventional Cardiology
Hamilton Health Sciences
Associate Professor
McMaster University
Hamilton, Ontario, Canada
Grant/Research Support: Bristol-Myers Squibb Company, GlaxoSmithKline, sanofi-aventis
Consultant: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and
Company, GlaxoSmithKline, Pfizer Inc, sanofi-aventis
Honorarium: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and
Company, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis

Sunil V. Rao, MD
Director of Interventional Cardiology
Veterans Administration Medical Center
Division of Cardiovascular Medicine
Duke University Medical Center
Durham, North Carolina
Grant Funding: Cordis Corporation, Momenta Pharmaceuticals, Portola Pharmaceuticals
Consultant: The Medicines Company, Bristol-Myers Squibb, Sanofi-Aventis
Speakers’ Bureau: The Medicines Company, Bristol-Myers Squibb, Sanofi-Aventis

Harold L. Dauerman, MD, FACC
Professor of Medicine
Director of Cardiovascular Catheterization Laboratories
University of Vermont Medical Center
Fletcher Allen Health Care
Burlington, VT
Consultant: The Medicines Company
Speaker’s Bureau: The Medicines Company

Program Managers and Disclosures

Gideon Bosker, MD
Nothing to Disclose

Milo Falcon
Nothing to Disclose

Denise Leary
Nothing to Disclose

Educational Objectives:

As a result of participating in this program, clinicians will be able to:

• Optimize anti-ischemic efficacy, while reducing bleeding related complications and adverse events in high risk, complex patients requiring antiplatelet therapy in the setting of PCI
• Compare anti-ischemic effects, mortality data, bleeding complications, and drug-drug interactions among indicated antiplatelet agents in the setting of cardiac catheterization
• Analyze, compare, and assess the clinical implications of recent landmark trials in antiplatelet therapy among them, the CURRENT-OASIS 7, PLATO, and TRITON-TIMI 38 trials; and how to make risk-directed decisions in the setting of PCI
• List the safety, efficacy, and mortality reducing implications of new dosing strategies for established oral antiplatelet therapies and their implications for PCI-based management of high risk ACS and STEMI
• Describe how to achieve the ideal balance between anti-ischemic efficacy and bleeding reduction in the cardiac catheterization laboratory
  

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved